# PeptideScanner evidence objects: Gallium Ga 68 dotatate

Every published version of the records placed with Gallium Ga 68 dotatate, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json. Selected public evidence only; not medical advice.

- Objects: 13
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct03206060-gallium-ga-68-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03206060

> PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03206060-gallium-ga-68-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03206060-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct03206060-gallium-ga-68-dotatate-v1
- Content SHA-256: `0e2e3b4795f279087fbba952b3a0e780967f98f058671df8658891e6a6d0b93a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03206060 ([`ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5`](#source-ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5`](#source-ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5`](#source-ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5`](#source-ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5))

### Sources

<a id="source-ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5"></a>
- **ClinicalTrials.gov record NCT03206060 · retained source version 2026-10-26:49cf7f72ecf561f74f8563b59065799bc0a357fb6e3636666768d5d28d96190c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03206060) (`ctg-observation-nct03206060-2026-10-26-49cf7f72ecf5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03206060." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct03206060-gallium-ga-68-dotatate-v1 SHA-256: 0e2e3b4795f279087fbba952b3a0e780967f98f058671df8658891e6a6d0b93a.

---

<a id="clinicaltrials-gov-nct03448458-gallium-ga-68-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03448458

> PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03448458-gallium-ga-68-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03448458-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct03448458-gallium-ga-68-dotatate-v1
- Content SHA-256: `2c0f4132fe7a797a2acb297410432d5c23369b6732ef9293656dea5d5728ed6c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03448458 ([`ctg-observation-nct03448458-2025-07-17-80a925d78e44`](#source-ctg-observation-nct03448458-2025-07-17-80a925d78e44))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct03448458-2025-07-17-80a925d78e44`](#source-ctg-observation-nct03448458-2025-07-17-80a925d78e44))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct03448458-2025-07-17-80a925d78e44`](#source-ctg-observation-nct03448458-2025-07-17-80a925d78e44))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03448458-2025-07-17-80a925d78e44`](#source-ctg-observation-nct03448458-2025-07-17-80a925d78e44))

### Sources

<a id="source-ctg-observation-nct03448458-2025-07-17-80a925d78e44"></a>
- **ClinicalTrials.gov record NCT03448458 · retained source version 2025-07-17:80a925d78e44e87a1a539fa3eb17f6b22b5f19adb2092ca016e108ee9e9497f7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03448458) (`ctg-observation-nct03448458-2025-07-17-80a925d78e44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03448458." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct03448458-gallium-ga-68-dotatate-v1 SHA-256: 2c0f4132fe7a797a2acb297410432d5c23369b6732ef9293656dea5d5728ed6c.

---

<a id="clinicaltrials-gov-nct03953131-gallium-ga-68-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03953131

> PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03953131-gallium-ga-68-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03953131-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct03953131-gallium-ga-68-dotatate-v1
- Content SHA-256: `55751f7792baff26e17f988bb0e236b90a3fd39d33825eef0410a136d99353be`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03953131 ([`ctg-observation-nct03953131-2023-09-01-bc7a98d0640d`](#source-ctg-observation-nct03953131-2023-09-01-bc7a98d0640d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct03953131-2023-09-01-bc7a98d0640d`](#source-ctg-observation-nct03953131-2023-09-01-bc7a98d0640d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct03953131-2023-09-01-bc7a98d0640d`](#source-ctg-observation-nct03953131-2023-09-01-bc7a98d0640d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03953131-2023-09-01-bc7a98d0640d`](#source-ctg-observation-nct03953131-2023-09-01-bc7a98d0640d))

### Sources

<a id="source-ctg-observation-nct03953131-2023-09-01-bc7a98d0640d"></a>
- **ClinicalTrials.gov record NCT03953131 · retained source version 2023-09-01:bc7a98d0640d25b0d6d10a04f22c288be67dc31450fb2ffa045f96085b02a311** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03953131) (`ctg-observation-nct03953131-2023-09-01-bc7a98d0640d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03953131." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct03953131-gallium-ga-68-dotatate-v1 SHA-256: 55751f7792baff26e17f988bb0e236b90a3fd39d33825eef0410a136d99353be.

---

<a id="clinicaltrials-gov-nct04040088-gallium-ga-68-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04040088

> PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04040088-gallium-ga-68-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04040088-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct04040088-gallium-ga-68-dotatate-v1
- Content SHA-256: `f68ad71995a4f16b5ae49c60345eca8f82a75f30d40f65a7a38f5bc8767b79c6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04040088 ([`ctg-observation-nct04040088-2026-03-31-cb7158b8edca`](#source-ctg-observation-nct04040088-2026-03-31-cb7158b8edca))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct04040088-2026-03-31-cb7158b8edca`](#source-ctg-observation-nct04040088-2026-03-31-cb7158b8edca))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct04040088-2026-03-31-cb7158b8edca`](#source-ctg-observation-nct04040088-2026-03-31-cb7158b8edca))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04040088-2026-03-31-cb7158b8edca`](#source-ctg-observation-nct04040088-2026-03-31-cb7158b8edca))

### Sources

<a id="source-ctg-observation-nct04040088-2026-03-31-cb7158b8edca"></a>
- **ClinicalTrials.gov record NCT04040088 · retained source version 2026-03-31:cb7158b8edca60e49d6b5f2f98990403cb36fac743df9542c85918cb57e21e05** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04040088) (`ctg-observation-nct04040088-2026-03-31-cb7158b8edca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04040088." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct04040088-gallium-ga-68-dotatate-v1 SHA-256: f68ad71995a4f16b5ae49c60345eca8f82a75f30d40f65a7a38f5bc8767b79c6.

---

<a id="clinicaltrials-gov-nct04069299-gallium-ga-68-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04069299

> PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04069299-gallium-ga-68-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04069299-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct04069299-gallium-ga-68-dotatate-v1
- Content SHA-256: `52e212b1ec35d34c1cdca029614b38978ea4a8ed6db92e5c34d72e9a2b1689da`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04069299 ([`ctg-observation-nct04069299-2026-03-31-5db2b265cd20`](#source-ctg-observation-nct04069299-2026-03-31-5db2b265cd20))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct04069299-2026-03-31-5db2b265cd20`](#source-ctg-observation-nct04069299-2026-03-31-5db2b265cd20))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct04069299-2026-03-31-5db2b265cd20`](#source-ctg-observation-nct04069299-2026-03-31-5db2b265cd20))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04069299-2026-03-31-5db2b265cd20`](#source-ctg-observation-nct04069299-2026-03-31-5db2b265cd20))

### Sources

<a id="source-ctg-observation-nct04069299-2026-03-31-5db2b265cd20"></a>
- **ClinicalTrials.gov record NCT04069299 · retained source version 2026-03-31:5db2b265cd206afe409a159a7d462f6ffaf3b1ce1f467af2c101fe53a8149d5f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04069299) (`ctg-observation-nct04069299-2026-03-31-5db2b265cd20`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04069299." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct04069299-gallium-ga-68-dotatate-v1 SHA-256: 52e212b1ec35d34c1cdca029614b38978ea4a8ed6db92e5c34d72e9a2b1689da.

---

<a id="clinicaltrials-gov-nct07150806-gallium-ga-68-dotatate-v1"></a>

## ClinicalTrials.gov record NCT07150806

> PeptideScanner retained ClinicalTrials.gov record NCT07150806 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct07150806-gallium-ga-68-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07150806-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct07150806-gallium-ga-68-dotatate-v1
- Content SHA-256: `3e30cd69956db03ff245ffed356039d803a5cfb3d734a5fd777178886bb0f650`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07150806 ([`ctg-observation-nct07150806-2026-08-13-271a33709bbb`](#source-ctg-observation-nct07150806-2026-08-13-271a33709bbb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07150806 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct07150806-2026-08-13-271a33709bbb`](#source-ctg-observation-nct07150806-2026-08-13-271a33709bbb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07150806 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate. ([`ctg-observation-nct07150806-2026-08-13-271a33709bbb`](#source-ctg-observation-nct07150806-2026-08-13-271a33709bbb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07150806-2026-08-13-271a33709bbb`](#source-ctg-observation-nct07150806-2026-08-13-271a33709bbb))

### Sources

<a id="source-ctg-observation-nct07150806-2026-08-13-271a33709bbb"></a>
- **ClinicalTrials.gov record NCT07150806 · retained source version 2026-08-13:271a33709bbb9803981c6fa49ba6304ffcb36256532a24adb83a0c2fe52912d0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07150806) (`ctg-observation-nct07150806-2026-08-13-271a33709bbb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07150806." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#clinicaltrials-gov-nct07150806-gallium-ga-68-dotatate-v1 SHA-256: 3e30cd69956db03ff245ffed356039d803a5cfb3d734a5fd777178886bb0f650.

---

<a id="fda-drugs-nda208547-v1"></a>

## Drugs@FDA application NDA208547

> The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208547:v1`
- Evidence domain: Regulatory
- Date in source: 2016-06-01
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208547/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#fda-drugs-nda208547-v1
- Content SHA-256: `1546b64bb89c321e478e9e78466c2b07591ff94e18e5856fb9123820dd803128`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208547 ([`fda-drugs-nda208547-2016-06-01-3d9c9d87d983`](#source-fda-drugs-nda208547-2016-06-01-3d9c9d87d983))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients. ([`fda-drugs-nda208547-2016-06-01-3d9c9d87d983`](#source-fda-drugs-nda208547-2016-06-01-3d9c9d87d983))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients. ([`fda-drugs-nda208547-2016-06-01-3d9c9d87d983`](#source-fda-drugs-nda208547-2016-06-01-3d9c9d87d983))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208547-2016-06-01-3d9c9d87d983`](#source-fda-drugs-nda208547-2016-06-01-3d9c9d87d983))

### Sources

<a id="source-fda-drugs-nda208547-2016-06-01-3d9c9d87d983"></a>
- **Drugs@FDA application NDA208547 · original submission status AP · 2016-06-01 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208547%22&limit=1) (`fda-drugs-nda208547-2016-06-01-3d9c9d87d983`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208547." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#fda-drugs-nda208547-v1 SHA-256: 1546b64bb89c321e478e9e78466c2b07591ff94e18e5856fb9123820dd803128.

---

<a id="pubmed-pmid-34096898-gallium-ga-68-dotatate-v1"></a>

## Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors.

> PubMed lists PMID 34096898 in Topics in magnetic resonance imaging : TMRI as Journal Article, Review, with publication-date metadata of 2021-06-01 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34096898-gallium-ga-68-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34096898-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-34096898-gallium-ga-68-dotatate-v1
- Content SHA-256: `0328bc87add0e0713ecec7dc48c0e3ab21d14be8227306214fd91f203d74cb96`

### Claims and source pins

#### Headline

Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors. ([`pubmed-observation-pmid-34096898-2021-06-16-a122523861a2`](#source-pubmed-observation-pmid-34096898-2021-06-16-a122523861a2))

#### Summary

PubMed lists PMID 34096898 in Topics in magnetic resonance imaging : TMRI as Journal Article, Review, with publication-date metadata of 2021-06-01 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34096898-2021-06-16-a122523861a2`](#source-pubmed-observation-pmid-34096898-2021-06-16-a122523861a2))

#### Paragraph 1

PubMed lists PMID 34096898 in Topics in magnetic resonance imaging : TMRI as Journal Article, Review, with publication-date metadata of 2021-06-01 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34096898-2021-06-16-a122523861a2`](#source-pubmed-observation-pmid-34096898-2021-06-16-a122523861a2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34096898-2021-06-16-a122523861a2`](#source-pubmed-observation-pmid-34096898-2021-06-16-a122523861a2))

### Sources

<a id="source-pubmed-observation-pmid-34096898-2021-06-16-a122523861a2"></a>
- **Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors. · retained source version 1:2021-06-16:current:a122523861a2772cbcf64de4e74b63a2c1889761890c47caecb12bb428ece26d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34096898/) (`pubmed-observation-pmid-34096898-2021-06-16-a122523861a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-34096898-gallium-ga-68-dotatate-v1 SHA-256: 0328bc87add0e0713ecec7dc48c0e3ab21d14be8227306214fd91f203d74cb96.

---

<a id="pubmed-pmid-38262470-gallium-ga-68-dotatate-v1"></a>

## Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations.

> PubMed lists PMID 38262470 in Nuklearmedizin. Nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2024-01-23 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38262470-gallium-ga-68-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-02-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38262470-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38262470-gallium-ga-68-dotatate-v1
- Content SHA-256: `4259190f49a3e0d57e0eb24ccbad90a6b0e5c2e4b5d8f05703f8fe9fa9f01cbe`

### Claims and source pins

#### Headline

Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations. ([`pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0`](#source-pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0))

#### Summary

PubMed lists PMID 38262470 in Nuklearmedizin. Nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2024-01-23 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0`](#source-pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0))

#### Paragraph 1

PubMed lists PMID 38262470 in Nuklearmedizin. Nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2024-01-23 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0`](#source-pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0`](#source-pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0))

### Sources

<a id="source-pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0"></a>
- **Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations. · retained source version 1:2025-02-04:current:429a1ae32de03b6c58b567cc2466c9b52ce184368fb4a05b364f5f6175c180ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38262470/) (`pubmed-observation-pmid-38262470-2025-02-04-429a1ae32de0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38262470-gallium-ga-68-dotatate-v1 SHA-256: 4259190f49a3e0d57e0eb24ccbad90a6b0e5c2e4b5d8f05703f8fe9fa9f01cbe.

---

<a id="pubmed-pmid-38563291-gallium-ga-68-dotatate-v1"></a>

## The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1.

> PubMed lists PMID 38563291 in Journal of medical imaging and radiation oncology as Journal Article, with publication-date metadata of 2024-04-02 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38563291-gallium-ga-68-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-04-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38563291-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38563291-gallium-ga-68-dotatate-v1
- Content SHA-256: `0da1cff441123f3e1778ac2eea8589ea2e27c8fe8ced2042d1a27812cc4d442a`

### Claims and source pins

#### Headline

The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1. ([`pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3`](#source-pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3))

#### Summary

PubMed lists PMID 38563291 in Journal of medical imaging and radiation oncology as Journal Article, with publication-date metadata of 2024-04-02 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3`](#source-pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3))

#### Paragraph 1

PubMed lists PMID 38563291 in Journal of medical imaging and radiation oncology as Journal Article, with publication-date metadata of 2024-04-02 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3`](#source-pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3`](#source-pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3))

### Sources

<a id="source-pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3"></a>
- **The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1. · retained source version 1:2024-04-25:current:c0670cf437f339a0ce9d780ad386096b58a588d32f9e6d4b7ec395a0f9cfc812** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38563291/) (`pubmed-observation-pmid-38563291-2024-04-25-c0670cf437f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38563291-gallium-ga-68-dotatate-v1 SHA-256: 0da1cff441123f3e1778ac2eea8589ea2e27c8fe8ced2042d1a27812cc4d442a.

---

<a id="pubmed-pmid-38933071-gallium-ga-68-dotatate-v1"></a>

## Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging.

> PubMed lists PMID 38933071 in World journal of nuclear medicine as Journal Article, with publication-date metadata of 2024-05-07 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38933071-gallium-ga-68-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-06-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38933071-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38933071-gallium-ga-68-dotatate-v1
- Content SHA-256: `f24dd3a7af7b9ff15bab8e8aa2476c719b8b7b9f14f785011d782350220faba8`

### Claims and source pins

#### Headline

Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging. ([`pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb`](#source-pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb))

#### Summary

PubMed lists PMID 38933071 in World journal of nuclear medicine as Journal Article, with publication-date metadata of 2024-05-07 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb`](#source-pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb))

#### Paragraph 1

PubMed lists PMID 38933071 in World journal of nuclear medicine as Journal Article, with publication-date metadata of 2024-05-07 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb`](#source-pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb`](#source-pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb))

### Sources

<a id="source-pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb"></a>
- **Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging. · retained source version 1:2024-06-28:current:5860e73a62ebed0fd5a96f5583c8417fce114518eb6e97b8f55a92577a19aca8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38933071/) (`pubmed-observation-pmid-38933071-2024-06-28-5860e73a62eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38933071-gallium-ga-68-dotatate-v1 SHA-256: f24dd3a7af7b9ff15bab8e8aa2476c719b8b7b9f14f785011d782350220faba8.

---

<a id="pubmed-pmid-38967895-gallium-ga-68-dotatate-v1"></a>

## Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT.

> PubMed lists PMID 38967895 in The international journal of cardiovascular imaging as Journal Article, Validation Study, Comparative Study, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38967895-gallium-ga-68-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-11-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38967895-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38967895-gallium-ga-68-dotatate-v1
- Content SHA-256: `a4cd6f316230372dc887a0de3cefcf4896a10079a34e0da21c2f15e45896b932`

### Claims and source pins

#### Headline

Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. ([`pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945`](#source-pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945))

#### Summary

PubMed lists PMID 38967895 in The international journal of cardiovascular imaging as Journal Article, Validation Study, Comparative Study, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945`](#source-pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945))

#### Paragraph 1

PubMed lists PMID 38967895 in The international journal of cardiovascular imaging as Journal Article, Validation Study, Comparative Study, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945`](#source-pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945`](#source-pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945))

### Sources

<a id="source-pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945"></a>
- **Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. · retained source version 1:2024-11-25:current:63505f6b294578739710d9cf36f9e7005f5d3283a49a9e3756d14dce80a07f87** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38967895/) (`pubmed-observation-pmid-38967895-2024-11-25-63505f6b2945`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-38967895-gallium-ga-68-dotatate-v1 SHA-256: a4cd6f316230372dc887a0de3cefcf4896a10079a34e0da21c2f15e45896b932.

---

<a id="pubmed-pmid-42787917-gallium-ga-68-dotatate-v1"></a>

## Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation.

> PubMed lists PMID 42787917 in World journal of nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42787917-gallium-ga-68-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42787917-gallium-ga-68-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-42787917-gallium-ga-68-dotatate-v1
- Content SHA-256: `d13538197a5cdb7d54df6812d058688b17c4cc39bd5a64f37e5a289af11df65d`

### Claims and source pins

#### Headline

Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation. ([`pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40`](#source-pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40))

#### Summary

PubMed lists PMID 42787917 in World journal of nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40`](#source-pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40))

#### Paragraph 1

PubMed lists PMID 42787917 in World journal of nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40`](#source-pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40`](#source-pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40))

### Sources

<a id="source-pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40"></a>
- **Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation. · retained source version 1:2026-09-26:current:a5ba0aa13e40e90eb658e40621083b668672c25e1135b17f53e7fe99ec59ddba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42787917/) (`pubmed-observation-pmid-42787917-2026-09-26-a5ba0aa13e40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/gallium-ga-68-dotatate.json#pubmed-pmid-42787917-gallium-ga-68-dotatate-v1 SHA-256: d13538197a5cdb7d54df6812d058688b17c4cc39bd5a64f37e5a289af11df65d.

